What Trump's generic drug tariffs could mean, according to experts
Summarized and contextualized by DistantNews.
At a glance
- President Trump announced plans to impose tariffs of up to 100% on imported generic drugs, starting in 2028.
- The measure aims to incentivize manufacturers to move production back to the U.S., a goal experts view with skepticism.
- The U.S. currently relies heavily on India and China for generic drug manufacturing, raising concerns about potential price increases for consumers.
President Trump announced plans to impose tariffs of up to 100% on imported generic drugs, with the measure set to begin in August 2028 and increase to 200% after one year. The stated goal of this policy is to "RESHORE Generic Pharmaceutical Production into America," according to a post on Truth Social.
A tariff can be part of a broader strategy, but is not going to by itself lead to onshoring.
This initiative could significantly alter the generic drug industry, which supplies 90% of prescriptions filled in the U.S. Over the past decades, generic drug manufacturing has increasingly shifted overseas, with India now supplying over half of the generic prescriptions in the U.S. The U.S. also relies heavily on China for essential medications like ibuprofen, acetaminophen, and penicillin.
Health policy experts express skepticism about the tariffs' effectiveness in solely driving manufacturers to relocate production. Marta Wosiลska, a senior fellow at the Brookings Institution's Center on Health Policy, stated that tariffs can be part of a broader strategy but are unlikely to achieve onshoring on their own. White House spokesman Kush Desai indicated that the administration provides a two-year runway and points to other policies, such as full equipment expensing, to aid the transition.
This is done in order to RESHORE Generic Pharmaceutical Production into America.
Experts also anticipate potential impacts on drug prices. Mariana Socal, an associate professor at Johns Hopkins Bloomberg School of Public Health, noted that generic drug manufacturers operate on slim margins, making it difficult for them to absorb tariff costs. She suggested that any changes are likely to be passed on to consumers, although competition and existing contracts might limit immediate price hikes. Wosiลska added that if prices do increase, the impact on consumers would be relatively modest due to the generally low cost of generic drugs.
Any changes to the tariff structure are likely to be passed through to the consumer.
Originally published by CBS News. Summarized and contextualized by our editorial team with added local perspective. Read our editorial standards.